# QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer

> **NCT07342283** · PHASE2 · RECRUITING · sponsor: **Affiliated Hospital of Nantong University** · enrollment: 30 (estimated)

## Conditions studied

- Triple Negative Breast Cancer (TNBC)

## Interventions

- **DRUG:** Immunotherapy combined with chemotherapy

## Key facts

- **NCT ID:** NCT07342283
- **Lead sponsor:** Affiliated Hospital of Nantong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-25
- **Primary completion:** 2027-12-25
- **Final completion:** 2028-12-25
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07342283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07342283, "QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07342283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*